Original Articles
Copyright ©The Author(s) 2000. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jun 15, 2000; 6(3): 339-343
Published online Jun 15, 2000. doi: 10.3748/wjg.v6.i3.339
Review of 336 patients with hepatocellular carcinoma at Songklanagarind Hospital
Pasiri Sithinamsuwan, Teerha Piratvisuth, Wiwatana Tanomkiat, Nualta Apakupakul, Surat Tongyoo
Pasiri Sithinamsuwan, Teerha Piratvisuth, Surat Tongyoo, Department of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand
Wiwatana Tanomkiat, Department of Radiology, Prince of Songkla University, Hat Yai, Songkhla, Thailand
Nualta Apakupakul, Department of Epidemiology, Prince of Songkla University, Hat Yai, Songkhla, Thailand
Author contributions: All authors contributed equally to the work.
Correspondence to: Pasiri Sithinamsuwan MD, Department of Medicine, Songklanakarind Hospital, Hat Yai, Songkhla 90110, Thailand. Pasiri@Kichimail.com
Fax: +66-74-429385
Received: March 15, 2000
Revised: April 3, 2000
Accepted: April 26, 2000
Published online: June 15, 2000
Abstract

AIM: To determine the clinical presentations, survival and prognostic factors of hepatocellular carcinoma (HCC) in Southern Thailand.

METHODS: Retrospective analysis was performed on the 336 hepatocellular carcinoma patients treated at Songklanagarind hospital between 1 January 1991 and 31 January 1999.

RESULTS: Of these 336 patients, 276 were males and 60 were females. The mean age was 54.4 years. The common symptoms and signs were abdominal pain and hepatomegaly. The most common presentation of tumor was a dominant mass with daughter nodules. Portal vein involvement was found in 50% of total. Extra hepatic metastasis was found in 13%, and the lung was the most common site. There were 65.4% with evidence of cirrhosis and half of them were in Child's class B. HBsAg was positive in 72.6%. Regarding Okuda's tumor staging, 15%, 61% and 24% were stage I, II and III, respectively. Overall median survival was 2.1 months (11.5, 2.6 and 0.7 months for stage I, II and III respectively). Treatments of HCC improved patient survival (5.5 months vs 1.6 months for untreated patients). Most common causes of death were hepatic failure. Using multivariate analysis, the prognostic factors identified were tumor staging, alpha-fetoprotein level above 10000 μg·L-1, extrahepatic metastasis, portal vein thrombosis and treatment.

CONCLUSION: HCC in Thailand is a fatal disease with poor outcome due to late presentation and high prevalence of liver cirrhosis. Early detection and proper management may improve outcome.

Keywords: hepatoma/therapy; biopsy; neoplasm staging; survival analysis; neoplasms metastasis; prognosis; drug therapy